The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya.
HIV
PrEP
cost analysis
cost-effectiveness
health economics
prevention
women
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
31
10
2018
accepted:
08
05
2019
entrez:
23
7
2019
pubmed:
23
7
2019
medline:
10
7
2020
Statut:
ppublish
Résumé
Understanding the cost of strategies to reach and deliver pre-exposure prophylaxis (PrEP) to priority populations is essential to assess the cost-effectiveness and budget impact of HIV prevention programmes. Providing PrEP through maternal and child health and family planning clinics offers a promising strategy to reach women in high HIV burden settings. We estimated incremental costs and explored the cost drivers of integrating PrEP delivery into routine maternal and child health and family planning services in Kenya. We conducted a costing study from the provider perspective within the PrEP Implementation for Young Women and Adolescents programme in western Kenya. We identified all within- and above-facility activities supporting PrEP delivery and measured clinical service time using time-and-motion studies. We obtained input costs from programme budgets, expenditure records and staff interviews. We estimated changes in costs if creatinine testing were postponed from initiation to first follow-up visit and if PrEP were prioritized to clients at high HIV risk using a behavioural risk assessment tool. We also projected costs under Ministry of Health (MOH) implementation assuming MOH salaries and programme supervision. We estimated annual numbers of PrEP visits from programme data abstracted from 16 facilities between November 2017 and June 2018. We report the cost per client-month of PrEP dispensed in 2017 USD. For an annual programme output of 24,005 screenings, 4198 PrEP initiations and 4427 follow-up visits, the average cost per client-month of PrEP dispensed in the study was $26.52. Personnel, drugs and laboratory tests comprised 43%, 25% and 14% of programme costs respectively. Postponing creatinine testing and prioritizing PrEP delivery to clients at high HIV risk reduced total programme costs by 8% and 14% respectively. In the MOH scenario assuming no changes in outputs, the projected cost per client-month of PrEP dispensed decreased to $16.54 and total programme costs decreased by 38%. Incremental PrEP costs are sensitive to the service delivery strategy used to engage priority populations. Postponing creatinine testing and prioritizing PrEP delivery to clients at high HIV risk may reduce costs. Context-specific cost data are crucial to assess the cost-effectiveness and affordability of PrEP delivery models.
Identifiants
pubmed: 31328443
doi: 10.1002/jia2.25296
pmc: PMC6643078
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25296Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007266
Pays : United States
Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Curr Opin HIV AIDS. 2016 Jan;11(1):80-6
pubmed: 26575147
Hum Resour Health. 2017 Apr 13;15(1):29
pubmed: 28407810
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Curr Opin HIV AIDS. 2016 Jan;11(1):56-66
pubmed: 26569182
AIDS. 2013 Jan 28;27(3):447-58
pubmed: 23296196
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25296
pubmed: 31328443
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S145-53
pubmed: 27355502
AIDS. 2015 Sep 24;29(15):2025-33
pubmed: 26352880
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
Retrovirology. 2018 Apr 2;15(1):29
pubmed: 29609619
J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21104
pubmed: 27760682
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):590-595
pubmed: 30204720
PLoS Med. 2011 Nov;8(11):e1001123
pubmed: 22110407
PLoS Med. 2013;10(3):e1001401
pubmed: 23554579
Lancet HIV. 2017 May;4(5):e214-e222
pubmed: 28233660
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20013
pubmed: 26198348
Hum Resour Health. 2010 Mar 31;8:8
pubmed: 20356363
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20227
pubmed: 26198350
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19946
pubmed: 26198340
AIDS. 2015 Mar 27;29(6):733-8
pubmed: 25849836
J Int AIDS Soc. 2017 Feb 8;20(1):21234
pubmed: 28362073
PLoS One. 2010 Nov 05;5(11):e13646
pubmed: 21079767
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):206-211
pubmed: 29135656
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256
Lancet. 2014 Jul 19;384(9939):249-56
pubmed: 25042235
PLoS One. 2013;8(3):e59549
pubmed: 23527217
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):221-8
pubmed: 24694930
AIDS. 2015 Sep 24;29(15):2035-44
pubmed: 26355574